C. Michael Gibson
Charles Michael Gibson | |
|---|---|
| Add a Photo | |
| Nationality | American |
| Citizenship | United States of America |
| Occupation |
|
Charles Michael Gibson, M.S., M.D., known professionally as C. Michael Gibson, is an interventional cardiologist at Beth Israel Deaconess Medical Center, cardiovascular researcher, and professor at Harvard Medical School.[1] He is best known for inventing the TIMI frame count and the TIMI myocardial perfusion grade, measures of coronary blood flow.
History
Gibson was born and raised in Tulsa, Oklahoma. He attended the University of Chicago and the University of Chicago Pritzker School of Medicine where he earned his Bachelor of Science, Master of Science, and Doctor of Medicine (MD) degrees in Biology and Medicine.[2] In 1989, Gibson completed his internship and residency in Internal Medicine at Brigham and Women's Hospital at Harvard Medical School.[2] From 1989 to 1993, he was a fellow at Beth Israel Deaconess Medical Center at Harvard Medical School.[2]
Gibson returned in 1992 to Brigham to serve as Chief Medical Resident. He subsequently held positions as Director of the Coronary Care Unit of Beth Israel Deaconess Medical Center, Director of the Cath Lab and Chief of Cardiology at the West Roxbury Veterans Administration Hospital. He served as Cath Lab Director and Associate Chief of Cardiology at University of California, San Francisco before coming back to Boston where he served as Associate Chief of Cardiology of Beth Israel Deaconess Medical Center.[3]
Career
Gibson is most well-known as the inventor of the TIMI frame count and the TIMI myocardial perfusion grade, measures of coronary blood flow. He also led the first large trial (the PIONEER trial) to show that dual therapy with an antiplatelet and an anticoagulant is superior to triple therapy with two antiplatelet agents in patients with atrial fibrillation who require a stent. He was appointed CEO of the BAIM Institute for Clinical Research, a non-profit academic research organization (ARO) known formerly as Harvard Clinical Research Institute (HCRI).[3] Gibson founded and is Editor-in-Chief of WikiDoc, an online open source encyclopedia of medicine.[4] He was medical lead while partnering with Microsoft, Google, and Yahoo! to design Schema.org, a system of content classification to improve medical search results.[5]
Gibson founded and leads PERFUSE, an academic research organization.[3] He has been principal investigator and/or led core services for 106 clinical trials. Under Gibson, PERFUSE built a master database consisting of TIMI studies spanning 25 years and involving 100,000 patients.[6] He has led phase 1-4 clinical trials and cardiology megatrials exceeding 30,000 patients.[6] Gibson is an at-large member of the US food and drug administration|US Food and Drug Administration’s cardiorenal panel having served as a standing member from 2017 to 2021.
In a 2021 peer-reviewed article in AIMS Public Health, Gibson was ranked the #1 cardiology influencer on Twitter.[7]
References
- ↑ Malamut, Melissa (2013-04-18). "Ask the Expert: What is Broken Heart Syndrome?". Boston Magazine. Retrieved 2023-03-06.
- ↑ 2.0 2.1 2.2 "Dr. C. Michael Gibson, MD". US News & World Report.
- ↑ 3.0 3.1 3.2 "C. Michael Gibson, MD". BAIM Institute for Clinical Research.
- ↑ "User:C Michael Gibson - wikidoc". www.wikidoc.org. Retrieved 2023-03-06.
- ↑ "Schema.org - Schema.org". schema.org. Retrieved 2023-03-06.
- ↑ 6.0 6.1 "C. Michael Gibson, MD, MSCAI | SCAI". scai.org. Retrieved 2023-03-06.
- ↑ Kesiena, Onoriode; Henry K, Onyeaka; Setri, Fugar; Alexis K, Okoh; Annabelle Santos, Volgman (2021-10-26). "The top 100 Twitter influencers in cardiology". AIMS Public Health (8(4)): 743–753 – via PubMed Central.
External links
This article "C. Michael Gibson" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.